WHY IT MATTERS: For the millions of patients with fatty liver disease who have limited pharmacological options, cannabinoid-based therapies could represent a meaningful new direction in treatment if ongoing clinical trials confirm these early findings. CLINICAL OVERVIEW: Emerging research suggests that cannabinoids, including both THC and CBD, may play a protective role against the development and progression of non-alcoholic fatty liver disease (NAFLD) by modulating hepatic inflammation, lipid metabolism, and fibrotic pathways through the endocannabinoid system. The liver expresses both CB1 and CB2 receptors, and while CB1 activation has historically been associated with pro-steatotic effects, selective CB2 stimulation appears to confer anti-inflammatory and antifibrotic benefits.